Meeting
2017 ASCO Annual Meeting
Clinical utilization of Breast Cancer Index (BCI) for late recurrence risk assessment and prediction of extended endocrine therapy (EET) benefit in early stage HR+ breast cancer.
Authors
Reshma L. Mahtani
Sylvester Comprehensive Cancer Center University of Miami Health System, Deerfield Beach, FL
Reshma L. Mahtani , Vijayakrishna K. Gadi , Theresa N. Operana , Harris S Soifer , Brock Schroeder , Catherine A. Schnabel , Lee Steven Schwartzberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 551)
DOI
10.1200/JCO.2017.35.15_suppl.551
Abstract #
551
Poster Bd #
151
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Predictive testing for selection of patients for extended endocrine therapy: Clinical utilization of Breast Cancer Index (BCI) in early-stage, ER+, LN- breast cancer.
First Author: Stephen C. Malamud
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
First Author: Diana Lüftner